FDA nixes use of aspirin for primary prevention

Share this article:

FDA issued a statement regarding aspirin's use in preventing heart attacks, saying it does not believe the evidence supports the general use of aspirin for primary prevention of a heart attack or stroke.

It comes after the agency denied a request from Bayer HealthCare, requesting a change in the prescribing information for HCPs (professional labeling) for aspirin to allow marketing of the product for prevention of heart attacks in patients with no prior history of cardiovascular disease.

The regulator stated yesterday that “after carefully examining scientific data from major studies, FDA has concluded that the data do not support the use of aspirin as a preventive medicine by people who have not had a heart attack, stroke or cardiovascular problems, a use that is called ‘primary prevention.'”

FDA did state, however, that “the available evidence supports the use of aspirin for preventing another heart attack or stroke in patients who have cardiovascular disease or who have already had a heart attack or stoke.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.